All In Biotech

Drug Trial Radar · NCT05630846

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age

Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 801 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

801

Actual

Start

Dec 14, 2022

Primary completion

Jun 7, 2024

Study completion Oct 14, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.

Conditions

  • Measles; Mumps; Rubella; Chickenpox
  • Measles

Interventions

  • Investigational MMRV(H)NS vaccineBiological

    1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.

  • Investigational MM(H)RVNS vaccineBiological

    1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.

  • Investigational M(L)M(L)R(L)V(L)NS vaccineBiological

    1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.

  • Marketed MMRV_Lot 1 and Lot 2 vaccineBiological

    1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GMC of Anti-measles Antibodies at Day 43Time frame: At Day 43
  2. GMC of Anti-mumps Antibodies at Day 43Time frame: At Day 43
  3. GMC of Anti-rubella Antibodies at Day 43Time frame: At Day 43
  4. GMC of Anti-glycoprotein E (gE) Antibodies at Day 43Time frame: At Day 43

Locations

47 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Bellflower, California

  • GSK Investigational Site

    Huntington Park, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Santa Clara, California

  • GSK Investigational Site

    West Covina, California

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Ammon, Idaho

  • GSK Investigational Site

    Idaho Falls, Idaho

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Lafayette, Louisiana

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Bingham Farms, Michigan

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Simpsonville, South Carolina

  • GSK Investigational Site

    Tullahoma, Tennessee

  • GSK Investigational Site

    Dickinson, Texas

  • GSK Investigational Site

    McAllen, Texas

  • GSK Investigational Site

    Richmond, Texas

  • GSK Investigational Site

    Layton, Utah

  • GSK Investigational Site

    Provo, Utah

  • GSK Investigational Site

    Roy, Utah

  • GSK Investigational Site

    South Jordan, Utah

  • GSK Investigational Site

    Barranquilla, Colombia

  • GSK Investigational Site

    Barranquilla, Colombia

  • GSK Investigational Site

    Bogotá, Colombia

  • GSK Investigational Site

    Riga, Latvia

  • GSK Investigational Site

    San Juan, Puerto Rico

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.